Baseline characteristics of the study population
T2DM
AMI, UNSTABLE ANGINA
Forty-two patients (IGT n = 27; T2DM n = 15; AMI = 36; unstable angina = 6) fulfilled the selection criteria and were randomized to receive either empagliflozin 25 mg/day (n = 20) or placebo (n = 22). Among those randomized to empagliflozin, the proportion of patients with IGT was 60% and T2DM 40%. The corresponding proportions in the placebo group were 68% and 32% respectively. The two groups were well balanced as regards baseline characteristics (Table 